Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841238 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT05841238 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 52 participants.
The verdict
NCT05841238, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
Interventions
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05841238
The ClinicalTrials.gov registry entry for NCT05841238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3502970 is the first listed.
NCT05841238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05841238 about?
NCT05841238 is a clinical study titled "A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants". The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also ...
What is the current status of trial NCT05841238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2023-04-26. Estimated completion is 2023-11-13.
What interventions are being tested in trial NCT05841238?
The interventions under investigation include: LY3502970 (DRUG).
Who is sponsoring clinical trial NCT05841238?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.